Valcyte

Performance of Dr Reddy's Laboratories in July-September quarter is expected to be weak as profit is likely to plunge 59 percent year-on-year to Rs 298 crore on poor operational performance.

US biz may drag Dr Reddy's Q1, net seen down 27% at Rs 456 cr

US sales in Q1 is estimated at USD 270-276 million from USD 285 million (QoQ), due to pricing pressure in drugs such as Valcyte & Vidaza generic. Also, there may be some pressure in US due to market share loss in Sumatriptan auto-injector and Dacogen generic.

Despite 3% rise, best to sell Dr Reddy's on Nexium woes?

Brokerages are still cautious on the stock as troubles do not seem to end for the Indian pharma company.

Sun Pharma withdraws lawsuit filed against USFDA by Ranbaxy

Valcyte (valganciclovir hydrochloride) is an antiviral drug. It is used in cytomegalovirus infections of eye. Nexium (esomeprazole) is used to treat certain stomach and esophagus problems.

Dr Reddy's, Endo get FDA approval to launch generic Valcyte

The US Food and Drug Administration (FDA) said it has granted final approval to Indian drugmaker Dr Reddy's Laboratories and US firm Endo International Plc to make cheaper copies of Roche Holding AG's antiviral Valcyte.

Ranbaxy loses Valcyte exclusivity: An analysis

Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.

Impact of FDA import alert on Ranbaxy sentimental: Expert

If the companies' exclusivities which are still in the pipeline like Diovan and Valcyte are from this plant then there can be significant financial impact, says Sriram Rathi.

Ranbaxy rises after Nomura upgrades stock to 'buy'

Ranbaxy Laboratories shares gained 2 percent on Monday morning after Nomura Financial Advisory and Securities India upgraded the pharma major to "buy" from "neutral." The brokerage also raised its target price on the stock to Rs 475 from Rs 415.